These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

256 related items for PubMed ID: 17003916

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Cyclooxygenase-2 inhibitors, nonsteroidal anti-inflammatory drugs, and cardiovascular risk.
    Vardeny O, Solomon SD.
    Cardiol Clin; 2008 Nov; 26(4):589-601. PubMed ID: 18929233
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Letter by Cen regarding article, "Effect of celecoxib on cardiovascular events and blood pressure in two trials for the prevention of colorectal adenomas".
    Cen YY.
    Circulation; 2007 Mar 27; 115(12):e348; author reply e349. PubMed ID: 17389275
    [No Abstract] [Full Text] [Related]

  • 7. NSAID-induced gastrointestinal and cardiovascular injury.
    Ng SC, Chan FK.
    Curr Opin Gastroenterol; 2010 Nov 27; 26(6):611-7. PubMed ID: 20948372
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Drug insight: cyclo-oxygenase-2 inhibitors--a critical appraisal.
    Hinz B, Renner B, Brune K.
    Nat Clin Pract Rheumatol; 2007 Oct 27; 3(10):552-60; quiz 1 p following 589. PubMed ID: 17906610
    [Abstract] [Full Text] [Related]

  • 12. Cardiovascular risks of cyclooxygenase inhibition.
    Stacy ZA, Dobesh PP, Trujillo TC.
    Pharmacotherapy; 2006 Jul 27; 26(7):919-38. PubMed ID: 16803424
    [Abstract] [Full Text] [Related]

  • 13. Strategies to reduce the GI risks of antiplatelet therapy.
    Scheiman JM.
    Rev Cardiovasc Med; 2005 Jul 27; 6 Suppl 4():S23-31. PubMed ID: 17710073
    [Abstract] [Full Text] [Related]

  • 14. COX-2 inhibitors: complex association with lower risk of hospitalization for gastrointestinal events compared to traditional NSAIDs plus proton pump inhibitors.
    van der Linden MW, Gaugris S, Kuipers EJ, van Herk-Sukel MP, van den Bemt BJ, Sen SS, Herings RM.
    Pharmacoepidemiol Drug Saf; 2009 Oct 27; 18(10):880-90. PubMed ID: 19593747
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Risks and benefits of COX-2 inhibitors vs non-selective NSAIDs: does their cardiovascular risk exceed their gastrointestinal benefit? A retrospective cohort study.
    Rahme E, Nedjar H.
    Rheumatology (Oxford); 2007 Mar 27; 46(3):435-8. PubMed ID: 17255138
    [Abstract] [Full Text] [Related]

  • 17. Selective COX-2 inhibitors: a promise unfulfilled?
    Henry D, McGettigan P.
    Gastroenterology; 2007 Feb 27; 132(2):790-4. PubMed ID: 17261306
    [No Abstract] [Full Text] [Related]

  • 18. Balancing risks and benefits of cyclooxygenase-2 selective nonsteroidal anti-inflammatory drugs.
    Scheiman JM.
    Gastroenterol Clin North Am; 2009 Jun 27; 38(2):305-14. PubMed ID: 19446260
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Coxibs, non-steroidal anti-inflammatory drugs and cardiovascular risk.
    Hermann M, Ruschitzka F.
    Intern Med J; 2006 May 27; 36(5):308-19. PubMed ID: 16650196
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.